David A. Siegel Applied Genetic Technologies Corp Transaction History

Two Sigma Advisers, LP

  • $41.3 Billion
  • Q3 2024

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$0.29 - $0.89 $17,603 - $54,023
60,700 Added 137.8%
104,749 $28,000
Q2 2022

Aug 15, 2022
SELL
$0.62 - $1.1 $45,681 - $81,048
-73,680 Reduced 62.58%
44,049 $34,000
Q1 2022

May 16, 2022
SELL
$1.07 - $2.71 $184,575 - $467,475
-172,500 Reduced 59.44%
117,729 $126,000
Q4 2021

Feb 14, 2022
SELL
$1.87 - $2.91 $69,003 - $107,379
-36,900 Reduced 11.28%
290,229 $551,000
Q3 2021

Nov 15, 2021
BUY
$3.01 - $4.12 $594,475 - $813,700
197,500 Added 152.36%
327,129 $985,000
Q2 2021

Aug 16, 2021
SELL
$3.62 - $5.23 $173,398 - $250,517
-47,900 Reduced 26.98%
129,629 $507,000
Q1 2021

May 17, 2021
BUY
$3.94 - $8.19 $101,258 - $210,483
25,700 Added 16.93%
177,529 $900,000
Q4 2020

Feb 16, 2021
BUY
$3.99 - $5.7 $357,504 - $510,720
89,600 Added 143.98%
151,829 $621,000
Q2 2020

Aug 14, 2020
BUY
$3.0 - $6.9 $20,100 - $46,230
6,700 Added 12.07%
62,229 $345,000
Q1 2020

May 15, 2020
BUY
$2.36 - $9.86 $10,384 - $43,384
4,400 Added 8.61%
55,529 $182,000
Q3 2019

Nov 14, 2019
SELL
$2.59 - $4.16 $777 - $1,248
-300 Reduced 0.58%
51,129 $213,000
Q2 2019

Aug 14, 2019
SELL
$3.6 - $4.78 $64,440 - $85,562
-17,900 Reduced 25.82%
51,429 $195,000
Q1 2019

May 15, 2019
SELL
$2.62 - $4.44 $29,868 - $50,616
-11,400 Reduced 14.12%
69,329 $290,000
Q4 2018

Feb 14, 2019
BUY
$2.28 - $7.15 $111,542 - $349,792
48,922 Added 153.81%
80,729 $201,000
Q3 2018

Nov 14, 2018
BUY
$3.85 - $7.35 $54,285 - $103,635
14,100 Added 79.63%
31,807 $232,000
Q2 2018

Aug 14, 2018
BUY
$3.7 - $5.65 $1,850 - $2,825
500 Added 2.91%
17,707 $66,000
Q1 2018

May 15, 2018
SELL
$3.65 - $5.2 $14,600 - $20,800
-4,000 Reduced 18.86%
17,207 $66,000
Q4 2017

Feb 14, 2018
BUY
$3.4 - $4.15 $72,103 - $88,009
21,207
21,207 $76,000

About APPLIED GENETIC TECHNOLOGIES CORP

AGTC Quotes by TradingView
  • Ticker AGTC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 67,632,200
  • Description
  • Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Pha...
More about AGTC
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email